Kinnate Biopharma Inc. (NASDAQ:KNTE) Receives $8.15 Average Price Target from Brokerages

Kinnate Biopharma Inc. (NASDAQ:KNTE) has received an average rating of “Hold” from the five research firms that are currently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.15.

A number of equities analysts have issued reports on KNTE shares. Wedbush restated a “neutral” rating and set a $2.00 target price on shares of Kinnate Biopharma in a report on Wednesday, January 17th. William Blair lowered Kinnate Biopharma from an “outperform” rating to a “market perform” rating in a research report on Friday, February 16th. Finally, Stifel Nicolaus raised their price target on Kinnate Biopharma to $2.59 and gave the stock a “hold” rating in a research report on Monday, February 26th.

Institutional Investors Weigh In On Kinnate Biopharma

A number of hedge funds have recently modified their holdings of KNTE. BML Capital Management LLC raised its position in Kinnate Biopharma by 6.5% in the 1st quarter. BML Capital Management LLC now owns 498,851 shares of the company’s stock valued at $1,327,000 after buying an additional 30,641 shares during the last quarter. Deltec Asset Management LLC acquired a new stake in Kinnate Biopharma in the 1st quarter valued at approximately $2,766,000. Pale Fire Capital SE raised its position in Kinnate Biopharma by 214.3% in the 4th quarter. Pale Fire Capital SE now owns 220,555 shares of the company’s stock valued at $523,000 after buying an additional 150,381 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Kinnate Biopharma in the 4th quarter valued at approximately $33,000. Finally, Marquette Asset Management LLC acquired a new stake in Kinnate Biopharma in the 4th quarter valued at approximately $142,000. Institutional investors and hedge funds own 80.89% of the company’s stock.

Kinnate Biopharma Trading Down 0.4 %

Shares of KNTE opened at $2.65 on Friday. Kinnate Biopharma has a 1 year low of $1.04 and a 1 year high of $7.18. The stock has a market cap of $125.13 million, a P/E ratio of -0.95 and a beta of 1.38. The stock’s 50-day moving average price is $2.60 and its two-hundred day moving average price is $2.25.

Kinnate Biopharma Company Profile

Kinnate Biopharma Inc, a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.